What Does GSK’s GF Score\u2122 Tell Us?<\/p>\n
The GF Score\u2122 is a composite metric designed to assess a company\u2019s overall quality by combining financial strength, profitability, growth, valuation, and momentum factors. GSK\u2019s GF Score\u2122 of 70 out of 100 indicates a generally healthy company with solid fundamentals but some areas for improvement.<\/p>\n
Metric Rating GF Score\u2122 70 Financial Strength 5\/10 Profitability 8\/10 Growth 5\/10 Valuation 6\/10 Momentum 2\/10<\/p>\n
GSK\u2019s strongest area is profitability, with an 8\/10 rating reflecting healthy operating margins (20.7%) and net margins (14.52%). Financial strength is moderate at 5\/10, partly due to an Altman Z-Score in the grey zone (2.1), indicating some financial stress but no immediate bankruptcy risk. Growth is steady but unspectacular, while valuation and momentum scores suggest the stock is fairly valued with weak recent price momentum. For a deeper dive, visit the GSK stock page<\/a>.<\/p>\n What Are Gurus and Insiders Doing with GSK?<\/p>\n Institutional interest in GSK remains significant but cautious. GuruFocus tracks 16 premium gurus holding GSK, with 11 reducing their stakes and 6 adding to positions in recent quarters. This mixed activity signals some uncertainty or profit-taking among top investors, contrasting with a generally positive long-term view. Insider activity is minimal, with no reported insider purchases or sales in the past 12 months, indicating a lack of strong insider conviction either way.<\/p>\n What This Means for Investors<\/p>\n For income-focused investors, GSK presents a dividend yield that is attractive relative to many healthcare peers, supported by a moderate payout ratio that suggests the dividend is sustainable but not aggressively growing. The modest overvaluation indicated by GF Value\u2122 advises caution on valuation grounds, especially given the weak momentum and mixed institutional ownership trends. The recent positive clinical data on Shingrix may provide a catalyst for future growth, but investors should weigh this against the company\u2019s financial strength signals and dividend growth challenges. Those interested in dividend sustainability and healthcare exposure may find GSK worthy of consideration, but valuation discipline remains important. More insights and updated metrics are available on the GSK stock page<\/a>.<\/p>\n Frequently Asked Questions<\/p>\n What is GSK’s GF Score\u2122?<\/p>\n GSK\u2019s GF Score\u2122 is 70 out of 100, reflecting a company with solid profitability and moderate financial strength but weaker momentum. This score aggregates multiple financial and valuation factors to provide a snapshot of overall quality.<\/p>\n Is GSK’s dividend safe?<\/p>\n GSK\u2019s dividend yield of 3.51% and payout ratio of 57% suggest the dividend is reasonably sustainable, though a 5.7% decline in dividend growth over three years indicates potential challenges in increasing payouts going forward.<\/p>\n What is GSK’s P\/E ratio compared to historical?<\/p>\n The current trailing twelve months P\/E ratio is 16.27x, slightly above its 5-year median P\/E of 14.03x, indicating the stock trades at a modest premium relative to its historical valuation.<\/p>\n This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email\u00a0protected]<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"On August 26, 2026, new research published in Nature Medicine highlighted that GSK PLC\u2019s (NYSE: GSK) shingles vaccine,…\n","protected":false},"author":2,"featured_media":111607,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[623,20785,34328,45751,18],"class_list":["post-111701","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-article","tag-gsk","tag-gurufocus","tag-gurufocus-news","tag-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117163402443941437","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/111701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=111701"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/111701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/111607"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=111701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=111701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=111701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"2092690515421208576.png\"\/](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/08\/2092690515421208576.png\")
<\/p>\n